Loading PTCT detail
Loading ticker data...
Loading PTCT detail
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean.
PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Chart data unavailable
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) EVP Lee Scott Golden sold 829 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $67.99, for a total value of $56,363.71. Following the completion of the sale, the executive vice president directly
Phocas Financial Corp. lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 31.6% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,482 shares of the biopharmaceutical company's stock after selling 11,752 shares during the period. Phocas Financial Corp.'s holdings in PTC
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) insider Neil Gregory Almstead sold 52,003 shares of the business's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $69.04, for a total transaction of $3,590,287.12. Following the completion of the sale, the insider directly owned 60,137 shares of
Assenagon Asset Management S.A. cut its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 49.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,170 shares of the biopharmaceutical company's stock after selling 53,478 shares during the quarter.
WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors.
PTC Therapeutics (NASDAQ: PTCT - Get Free Report) and Axsome Therapeutics (NASDAQ: AXSM - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations. Insider and Institutional Ownership 81.5% of Axsome
Cinctive Capital Management LP purchased a new position in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 95,308 shares of the biopharmaceutical company's stock, valued at approximately $5,849,000. Cinctive Capital Management LP owned about 0.12% of PTC
WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock and 17,515 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees.
PTC Therapeutics, Inc. (PTCT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Leerink Global Healthcare Conference 2026 Transcript
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.
Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Elliott Boulding sold 3,019 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $69.48, for a total transaction of $209,760.12. Following the sale, the vice president directly owned 105,212 shares in the company,
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026 Monday, March 2 at 9:50 a.m.
PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Huntington's disease and Vatiquinone for Friedreich's ataxia, offer significant upside but carry clinical trial risks. PTCT's competitive edge lies in its oral small molecule platform, collaborative development model, and strong pricing power in ultra-rare disease markets.
